Class 2 Tumor Suppressor Gene Pathways for Therapeutic Applications in Hard-to-Treat Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 275
Special Issue Editor
Special Issue Information
Dear Colleagues,
Hard-to-treat (HTT) cancers are a group of malignant tumors that are difficult to treat with conventional cancer treatments such as surgery, chemotherapy or radiotherapy. These cancers are typically more advanced or aggressive and are more likely to recur after treatment, resulting in poor prognosis. Examples of HTT cancers are pancreatic cancer, liver cancer, ovarian cancer, brain tumors, esophageal cancer and some types of blood cancer, such as multiple myeloma. However, some cancer subtypes, such as basal-type breast and bladder cancers, can be considered as HTT cancers as well, since they are associated with aggressive diseases and unfavorable survival.
Furthermore, many HTT cancers are known to be difficult to treat effectively with targeted therapies based on driver alterations such as oncogenic mutations or gene fusions. In contrast to non-small cell lung cancer (NSCLC), a prime example of a tumor entity with efficiently treatable drivers, HTT cancers are often not efficiently treatable with these approaches.
This Special Issue will investigate to what extent the challenging treatment of HTT tumors could be complemented by epigenetic cancer therapies in the future. The focus will be on new approaches resulting from the understanding of epigenetic signaling pathways in the cancer cell. Of particular relevance here are class 2 tumor suppressor genes, which are silenced in tumors at the level of promoter DNA methylation. The Special Issue is intended to contribute to finding new ideas and starting points for the epigenetic therapy of HTT cancers. A first concept for this strategy has already been published by the Guest Editor recently: https://www.mdpi.com/2072-6694/14/18/4386.
Prof. Dr. Edgar Dahl
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hard-to-treat cancers
- HTT cancers
- class 2 tumor suppressor genes
- C2TSGs
- DNA methylation driver
- DNAme driver
- epigenetic therapies
- cancer drug development
- personalized cancer therapy
- tumor suppressor mimetics
